Diagnostic and therapeutic challenges in cutaneous and mucosal melanoma: a literature review.
References
- Spencer, KR, Mehnert, JM. Mucosal Melanoma: Epidemiology, Biology and Treatment. In: Kaufman, H., Mehnert, J. (eds) Melanoma. Cancer Treatment and Research, 2016; vol 167. Springer, Cham.
https://doi.org/10.1007/978-3-319-22539-5_13 . - Santeufemia DA, Palmieri G, Miolo G, Colombino M, Doro MG, Frogheri L, et al. Current Trends in Mucosal Melanomas: An Overview. Cancers (Basel). 2023 Feb 21;15(5):1356. doi: 10.3390/cancers15051356. PMID: 36900152; PMCID: PMC10000120.
- Rutkowski P. Wysocki PJ, Kozak K. et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. 2022; 18. DOI: 10.5603/2021.0042
- Napierała MJ, Czarnecka AM. Czerniak błon śluzowych — obraz kliniczny i leczenie na podstawie analizy serii przypadków. Onkologia w Praktyce Klinicznej – Edukacja, 2019; 5(4), 272–279.
https://doi.org/10.5603/owpk_edu.65505 - Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw. 2012 Mar;10(3):345–56. doi: 10.6004/jnccn.2012.0034. PMID: 22393195.
- Christmas D, Pappa C, Howell C, Daas M, Howell K, Dhar S, et al. Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors. J Pers Med. 2025 Nov 12;15(11):551. doi: 10.3390/jpm15110551. PMID: 41295253; PMCID: PMC12653355.
- WHO. Malignant skin melanoma mortality. Dostępne na:
https://platform.who.int/mortality/themes/theme-details/topics/indicator-groups/indicators/indicator-details/MDB/a-malignant-skin-melanoma . - Wojciechowska U, Barańska K, Miklewska M, Didkowska JA. Cancer incidence and mortality in Poland in 2020. Nowotwory. Journal of Oncology, 2023; 73(3), 129–145.
https://doi.org/10.5603/NJO.2023.0026 - Portal pacjent.gov.pl. Onkologia. Dostępne na:
https://onkologia.pacjent.gov.pl/ . - Rutkowski P. (red.), Nowe terapie systemowe u chorych na nowotwory skóry, wyd. 2, Gdańsk: Via Medica, 2025.
- Samudio-Scavone EM. Pigmented melanoma of the tongue. Instituto de Previsión Social. Case report. Cirugía paraguaya, 2023; 47(1), 33–35.
https://doi.org/10.18004/sopaci.2023.abril.33 - Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020 Apr;61:139–148. doi: 10.1016/j.semcancer.2019.09.013. Epub 2019 Oct 23. PMID: 31655118; PMCID: PMC7078020.
- Buchbinder EI, Weirather JL, Manos M, Quattrochi BJ, Sholl LM, Brennick RC, et al. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 Apr;10(8):2627–2635. doi: 10.1002/cam4.3789. Epub 2021 Mar 15. PMID: 33724703; PMCID: PMC8026918.
- Broit N, Johansson PA, Rodgers CB, Walpole ST, Newell F, Hayward NK, et al. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. Mol Cancer Res. 2021 Jun;19(6):991–1004. doi: 10.1158/1541-7786.MCR-20-0839. Epub 2021 Mar 11. PMID: 33707307.
- Beaudoux O, Oudart JB, Riffaud L, Visseaux L, Marchal A, Lebre AS, et al. Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review. Mol Diagn Ther. 2022 Mar;26(2):189–202. doi: 10.1007/s40291-021-00572-0. Epub 2022 Feb 23. PMID: 35195858.
- Nenclares P, Ap Dafydd D, Bagwan I, Begg D, Kerawala C, King E, et al. Head and neck mucosal melanoma: The United Kingdom national guidelines. Eur J Cancer. 2020 Oct;138:11–18. doi: 10.1016/j.ejca.2020.07.017. Epub 2020 Aug 20. PMID: 32829104.
- Aroldi F, Middleton MR. Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. Am J Clin Dermatol. 2022 May;23(3):331–338. doi: 10.1007/s40257-022-00681-4. Epub 2022 Mar 31. PMID: 35359259.
- Sharib J, Slingluff CL Jr, Beasley GM. Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. J Surg Oncol. 2022 Jan;125(1):28–33. doi: 10.1002/jso.26717. PMID: 34897715; PMCID: PMC8682801.
- Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Thompson JF, Peach H, et al. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Ann Surg Oncol. 2018 Sep;25(9):2541–2549. doi: 10.1245/s10434-018-6470-1. Epub 2018 May 30. Erratum in: Ann Surg Oncol. 2018 Dec;25(Suppl 3):991. doi: 10.1245/s10434-018-6612-5.. Thompson JF [added]. PMID: 29850955; PMCID: PMC6097739.
- Vecchiato A, Mocellin S, Del Fiore P, Tosti G, Ascierto PA, Corradin MT, et al. The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. BMC Cancer. 2021 Jan 5;21(1):8. doi: 10.1186/s12885-020-07705-4. PMID: 33402122; PMCID: PMC7786513.
- Jacobsen ES, Soleymani T. Mohs Micrographic Surgery for the Treatment of Cutaneous Melanomas of the Head and Neck. Oral Maxillofac Surg Clin North Am. 2022 May;34(2):263–271. doi: 10.1016/j.coms.2021.11.005. Epub 2022 Apr 12. PMID: 35428505.
- Etzkorn JR, Jew OS, Shin TM, Sobanko JF, Neal DE, Miller CJ. Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining for atypical intraepidermal melanocytic proliferation. J Am Acad Dermatol. 2018 Dec;79(6):1109–1116.e1. doi: 10.1016/j.jaad.2018.06.058. Epub 2018 Jul 10. PMID: 30003986.
- Williams GJ, Quinn T, Lo S, Guitera P, Scolyer RA, Thompson JF, et al. Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses. J Eur Acad Dermatol Venereol. 2025 Feb;39(2):416–425. doi: 10.1111/jdv.20138. Epub 2024 Jun 6. PMID: 38842170; PMCID: PMC11760679.
- Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 Jan 10;41(2):186–197. doi: 10.1200/JCO.22.01763. Epub 2022 Sep 27. PMID: 36166727; PMCID: PMC9839305.
- Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025 Jan 2;392(1):11–22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. PMID: 39282897; PMCID: PMC12080919.
- Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10;42(14):1619–1624. doi: 10.1200/JCO.23.02355. Epub 2024 Mar 7. PMID: 38452313; PMCID: PMC11095869.
- Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22. Erratum in: NEJM Evid. 2023 May;2(5):EVIDx2300104. doi: 10.1056/EVIDx2300104. PMID: 38320023.
- Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct;16(13):1389–98. doi: 10.1016/S1470-2045(15)00087-X. PMID: 26433819.
- Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, et al. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019 Oct;121(7):522–528. doi: 10.1038/s41416-019-0546-y. Epub 2019 Aug 16. PMID: 31417188; PMCID: PMC6889491.
- Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022 Dec 20;40(36):4178–4188. doi: 10.1200/JCO.21.02659. Epub 2022 Jul 21. Erratum in: J Clin Oncol. 2023 Apr 20;41(12):2301. doi: 10.1200/JCO.23.00385. PMID: 35862871; PMCID: PMC9916040.
- Cybulska-Stopa B, Rogala P, Czarnecka AM, Galus Ł, Dziura R, Rajczykowski M, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Res. 2020 Oct;30(5):465–471. doi: 10.1097/CMR.0000000000000662. PMID: 32221131.
- Edmond M, Nenclares P, Harrington K, Ap Dafydd D, Bagwan I, Begg D, et al. What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era? Head Neck. 2021 Nov;43(11):3498–3503. doi: 10.1002/hed.26849. Epub 2021 Aug 28. PMID: 34453460.
- Yao JJ, Zhang F, Zhang GS, Deng XW, Zhang WJ, Lawrence WR, et al. Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study. Cancer Manag Res. 2018 Dec 14;10:6985–6996. doi: 10.2147/CMAR.S185017. PMID: 30588103; PMCID: PMC6298389.
- Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 Sep;119(6):670–674. doi: 10.1038/s41416-018-0207-6. Epub 2018 Sep 11. PMID: 30202085; PMCID: PMC6173747.
- Shoushtari A, Wagstaff J, Ascierto P, et al. CheckMate 067: Long – term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020; 38(15_suppl): 10019–10019, doi: 10.1200/jco.2020.38.15_suppl.10019.
- Sergi MC, Filoni E, Triggiano G, Cazzato G, Internò V, Porta C, et al. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment. Curr Oncol Rep. 2023 Nov;25(11):1247–1258. doi: 10.1007/s11912-023-01453-x. Epub 2023 Sep 29. PMID: 37773078; PMCID: PMC10640506.
- Kozak K. Czerniak skóry i błon śluzowych. Onkologia w Praktyce Klinicznej – Edukacja. 2021;7(5):339–345. doi:10.5603/owpk_edu.85064.
Language: English
Page range: 157 - 176
Submitted on: May 12, 2026
Accepted on: May 27, 2026
Published on: Jun 30, 2026
Published by: The Medical Library named after S. Konopka in Warsaw
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 Jakub Dudek, Wiktoria Górecka, Aleksandra Dudek, Bartosz Gaweł, Grzegorz Sochań, Michał Górecki, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.